Chimerix Stock News

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Mike Sherman – President & Chief Executive Officer Michael Andriole – Chief Financial &

Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.

Chimerix (CMRX) stock is falling hard on Monday following the release of its earnings report for the first quarter of 2022. The post Chimerix (CMRX) Stock Plummets 60% After Q1 Earnings Disappointment

– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics –

Emergent BioSolutions Inc (NYSE: EBS) has agreed to acquire Chimerix Inc's (NASDAQ: CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups

Shares of Chimerix Inc. CMRX, +3.41% shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to

DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patient

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11 Pfizer Inc (

DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients f

Gainers: OraSure Technologies (OSUR) +5%, Iovance Biotherapeutics (IOVA) +4%, Marqeta (MQ) +3%, Chimerix (CMRX) +3%, Ribbon Communications (RBBN) +3%.Losers: Incannex Healthcare…

CMRX earnings call for the period ending December 31, 2021.

CMRX earnings call for the period ending December 31, 2021.

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2021 Results - Earnings Call Transcript

Chimerix (CMRX) delivered earnings and revenue surprises of -309.09% and 99.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?